


DIAGNOSIS OF TOXOPLASMOSIS

GENERALITIES

Toxoplasma gondii life cycle





1- ORIENTATION ARGUMENTS (HEMATOLOGY)

- Discrete mononucleosis syndrome
- Moderate hypereosinophily (generally $< 0.1\%$ in proportion)

2- PARASITOLOGICAL DIAGNOSIS

- Evidence of the parasite (or its constituents)
- On CSF, bronchoalveolar lavage, amniotic liquid, placenta, biopsies ...
- A- Microscope analysis
 - Mainly immunosuppressed
 - Giemsa staining or equivalent



- **B- Mouse inoculation**
 - Mainly **cerebral toxoplasmosis** (placenta, CSF)
 - Or **immunosuppressed** (diverse biological products)
 - **Long** technique (4 to 6 weeks) but 90% **reliable**
- **C- *In vitro* cell culture**
 - Same indications
 - But faster results (4 to 5 days)
 - Cells used
 - Human embryonic fibroblast (MRC 5)
 - Monocyte line (THP 1)
 - Staining (Giemsa ou fluorescence)
 - **Less used than PCR but sometimes useful:**
hemorrhagic samples (Hemoglobin inhibits Taq pol)

- **D- PCR**

- **Parasite DNA** investigation
- Different target-sequences can be amplified:
preferentially **B 1, P 30 genes...**
- **Limit: hemorrhagic sample** (\Rightarrow cell culture)

3- IMMUNOLOGICAL DIAGNOSIS

- A- Legislation

- Mandatory toxoplasmosis serology

- Declaration of pregnancy
 - Sampling of organs, tissues and cells (donor and recipient)
 - Checkup for HIV infection
 - **Diverse follow up** : pregnant woman without any previous contact with *Toxoplasma*, immunosuppression

– J.O. avril 1995 puis TNB version N° 37 (janvier 2012)
(France)

- All exams have to precise
 - The technique
 - The positivity threshold of the reagent (Name)
 - The reagent lot number
- The biologist should conclude
 - For the presence or absence of anti-*T. gondii* antibodies
 - **Probable** date of infection in case of positivity
 - Interpretation
- The biologist proposes the modalities of an eventual follow up
- Conservation of serums: at least 1 year at –30° C



Toxoplasmosis serology

Mandatory

- **Association of 2 different isotypes**
 - Titration of IgG in UI/mL
 - IgM investigation
- **Write an argued conclusion**
 - Interpretation of the serologic profile.
 - Modalities of follow up if necessary
- **Precise on the report:**
 - Techniques
 - Reagents
 - Positivity threshold value


**Conserve serums
Frozen for 1 year**

The report should mention :

- The techniques used
- The lot number, the laboratory name
- Positivity thresholds (significant) for the quantitative techniques
- The antigens used
- The titer in UI/mL of IgG anti-Tx
- Indicate the presence or absence of IgM anti-Tx
- Analyze the results and conclude
- Indicate the modalities of follow up

- **3 cases mentioned**
 - Case of immunosuppressed
 - Case of pregnancy
 - Case of newborn
- **Identification and titration**
 - **At least 2 different Ig isotypes** (including IgG)
 - By at least 2 different techniques (selected by the biologist)
 - Follow up: *idem* with an analysis of the previous serums in parallel in the same series


– Antibodies kinetics



- **Anti-*Toxoplasma* Ig M**
 - First to appear (8 to 10 days)
 - Recent or evolutive disease
 - Time? → has to be determined
- **Anti-*Toxoplasma* IgA**
 - Appear \approx in the mean time as IgM
 - Disappear before IgM \Rightarrow **very recent disease**
 - Not much used
- **Anti-*Toxoplasma* Ig G**
 - **Appear later (1 to 3 weeks)**
 - **Reach a threshold**
 - **Persist for life**



Evolution kinetics of anti-*Toxoplasma* antibodies



Seroconversion = negative serology → positive

The appearance of IgG allows to affirm the seroconversion



Toxoplasmosis serology: where are the problems?




- IgG+, IgM- : positive serology, immunized patient (IgG+).
- IgG-, IgM- : negative serology, non-immunized patient.
In pregnancy monthly follow-up, with a last control after delivery.
If immune deficiency semestrial follow-up
- IgG-, IgM- \Rightarrow IgG-, IgM+ \Rightarrow IgG+, IgM+
-, then possible seroconversion, confirmed seroconversion (IgG+)
- IgG ambiguous, IgM- : immunized or not?
- IgG+, IgM+ : residual IgM or recent toxoplasmosis ?

C- Techniques

- Standard serum
 - IgG titer in UI Ab antitoxo/ml; ex 300 UI/ml
- Always T + T- and Treagent

- **IFI**

- **Fixed antigen bound to a support (commercialised)**
- **IgG**
 - Threshold : 6 to 10 UI/mL
 - Human anti-IgG labeled with a fluorochrome
- **IgM (REMINGTON test)**
 - Threshold : 1/40- 1/50
 - Human Anti-IgM labeled with a fluorochrome
- **Careful of false**
 - Positive reactions
 - Negative reactions



- **E.L.I.S.A. (much used, non subjective reading)**
(Enzyme-Linked ImmunoSorbent Assay)

- **Soluble antigens (enriched in membrane fractions)**


- **IgG**

- **Positivity threshold: 8 to 10 UI/mL**

- **Some ELISA kits usable for IgM (mini Vidas®, Biomerieux)**

- **Avidity of IgG, increases with time (urea 6M)**

- **Avidity index to date the infection**



- **Techniques of immunobinding**
 - **Bound or soluble antigens**
 - **IgM, IgA**
 - **Principal :**
 - **Human anti-IgM bound to a solid support**
 - **The IgM of the serum are then captured**
 - **Methodologies : multiple**
 - **ISAgA (3 steps)**
 - **Antigen bound and digested by trypsin** (80% memb., 20% cyto.)
 - **Results expressed as an index or score**
 - **Positivity threshold : score 8+**
 - **ELISA-double sandwich (5 steps)**
 - **« Reverse-ELISA » (4 steps)**
 - **Very specific, very (too much?) sensitive**

ISAgA (Desmonts)

Human anti-IgM



Serum



Antigen



**NEGATIVE =
Sedimentation**



**POSITIVE =
Agglutination**

Toxoplasmosis and immunosuppression

TOXOPLASMOSIS:

- **Opportunistic parasitosis** → remains contemporary
- **Frequently starts** with the beginning of HIV disease (**CD4 ≤ 100/μl**)
- Can also be observed in cases of immunosuppression due to other causes than HIV:
 - Grafts
 - Neoplasia and their treatment
 - Other viruses

Toxoplasmosis in immunosuppressed:

- Serious disease
- **Fatal without or with late treatment** (except for isolated ocular localization)
- Classically
 - **Localized Tx**
 - **Disseminated Tx**
 - **But** generally not that clear-cut...



Toxoplasmosis in immunosuppressed




- Toxoplasmosis in immunosuppressed is fatal without treatment, except for isolated ocular localization
 - Reactivation of a former toxoplasmosis
 - Primary infection in immunosuppressed
- Severity of the disease more linked to immunological state of the patient than the parasite genotype (Ajzenberg, J. Infect. Dis. 2009)
 - HIV immunosuppressed : more cerebral localizations
 - Non HIV immunosuppressed : more pulmonary localizations



Toxoplasmosis in immunosuppressed

- **Reactivation of a former toxoplasmosis**

- HIV infection & CD4 < 100 mm³
- Bone marrow graft +++



Rupture of a cyst

Tachyzoites multiplication & tissue necrosis

- **Primary infection in immunosuppressed**

- Solid Organ Transplantation (SOT), mainly heart (donor toxo + / recipient toxo-)
- Primary infection in immunosuppressed without prophylaxis



Biological diagnosis of toxoplasmosis in immunosuppressed

- **Positive serology** : possible diagnosis of a toxoplasmosis.
- **Negative serology** :
diagnosis of a toxoplasmosis excluded, except for the beginning of a primary infection.

Possible delay for the seroconversion : associate serology and parasite detection

- **Diagnosis of certainty:**
→ evidence of the parasite

Can be due to:

- **Reactivation of a former toxoplasmosis (secondary)**
 - Important deficiency of cellular immunity
 - Often **HIV+ with $CD4 \leq 100/\mu L$**
 - **Serology \pm contributive, preferable to perform a direct diagnosis**

Can be due to:

- **A primary infection:**
 - Often **secondary** to the transmission of a graft (solid organ: **heart +++**)
 - Sometimes with alimentary origin
 - **Contributive serology (but sometimes synthesis of antibodies is delayed, so it should be associated with a direct detection of the parasite)**

Toxoplasmosis serology and immunosuppression

- Mandatory in all grafts
 - Donor
 - Recipients

Toxoplasmosis serology

- Example of grafts


- Heart

- **D Tx+ et R Tx- → high risk** (no immunization in R, heart = muscle, highly infected, more than other solid organ)
 - **D Tx- et R Tx+ → low risk** (reactivation of IgG)

- Bone marrow

- **D Tx- et R Tx+ → high risk** (immunosuppressive treatment longer than for SOT)
 - **D Tx+ et R Tx- → low risk** (passive transfer of lymphocytes)

FIGURE. Phases of opportunistic infections among allogeneic HSCT recipients



Type of transplant	Type of risk	
	Donor-transmitted disease	Reactivation
SOT		
Heart/heart-lung transplant	High in D ⁺ /R ⁻	Low even in R ⁺ None in R ⁻
Liver	Low in D ⁺ /R ⁻	Low in R ⁺ None in R ⁻
Kidney	Low in D ⁺ /R ⁻	Low in R ⁺ None in R ⁻
Intestine	Low in D ⁺ /R ⁻	None in R ⁻
HSCT		
Autologous	No risk	Nil in R ⁻ Very low in R ⁺
Allogeneic	No risk	High in R ⁺ Risk more if donor seronegative

D⁺: Pretransplant donor antitoxoplasma serology positive, R⁺: Pretransplant recipient antitoxoplasma serology positive, R⁻: Pretransplant recipient antitoxoplasma serology negative, SOT: Solid organ transplant, HSCT: Hematopoietic stem cell transplant

- Tx serology mandatory during a
checkup for HIV infection

– **Patient Tx-**

- Tx serology at least 3 times a year
- During the whole time of immunosuppression

– **Patient Tx+**

- Serology not much contributive
- UNLESS
- Important increase of antibodies, showing a
clinical reactivation at \pm long term

Direct parasitological diagnosis

- Direct detection on biological products, biopsies: low sensitivity
- qPCR+++ (blood, bone marrow, BAL, CSF) specificity and sensitivity ++++
- Indirect techniques
 - Mouse inoculation (slow, 30 days)
 - Cellular culture (1 week)

Treatment and prophylaxis

If patient Tx-, indicate in the report the hygiemo-dietetic rules to follow
No real consensus in other situations of immunosuppression, apart from HIV

Curative treatment Cerebral Tx	Primary prophylaxis Tx	Secondary prophylaxis Cerebral Tx or maintenance treatment	Stop / Resurgence/ HAART
Pyrimethamine, folinic acid and sulfadiazine (or clindamycine or atovaquone) 3 to 6 weeks	BACTRIM	Pyrimethamine and folinic acid and sulfadiazine (or clindamycine) Reduced doses (1/2)	Stop if : ➤ >200 / μ l CD4, analyzed twice at 3 months interval ➤ and undetectable viral burden
	Dapsone, Pyrimethamine and Folinic acid		
Association with anticonvulsant treatment	CD4 < 100 / μ l (possibility to stop the prophylaxy if CD4 > 200 for at least 3 months)		Resurgence when CD4 < 350 / μ l
Anti-oedematous treatment Corticoides ? !!!			

- Advices for ID Tx- patients:
 - Sufficient cooking of meat before consumption
 - **All meats (white or red)**
 - **Cooking $\geq 65^{\circ} \text{ C}$ (internal temperature)**
 - **Avoid consumption of marinated, grilled or smoked meats**

- **During meals preparation:**
 - **Wash well vegetables**, especially if they are earthy and eaten raw.
 - **Wash well cooking tools** and the bench.
 - **Wash hands** after contact with vegetables, fruits or raw meat before eating.

- **During meals outside the home:**

- Avoid consumption of raw vegetables and prefer cooked vegetables
- Meat should be eaten well cooked and prefer consumption of fish.

- **Avoid direct contact** with objects that could have been contaminated **by cat feces** (litter, soil...) and **wear gloves** in case of their manipulation.
- Disinfect cat litter with bleach
- **Avoid direct contact with soil and wear gloves to garden. Wash hands after gardening activities** even if they were protected by gloves.